Imugene’s Capital Raise and Debt Restructure Could Dilute Shareholders

Capital Raise Overview

Imugene Limited (ASX:IMU), a clinical-stage immuno-oncology company, has announced a significant $20 million capital raise aimed at advancing its lead cell therapy candidate, azer-cel. The raise comprises a $12 million institutional placement and an $8 million Share Purchase Plan (SPP) offered to existing eligible shareholders at a price of $0.18 per share, representing a discount of around 21% to recent trading prices.

The placement attracted strong support from both new and existing domestic and international institutional investors, underscoring confidence in Imugene’s clinical development strategy. The SPP, capped at $8 million, allows shareholders to invest up to $30,000 each, with institutional investors committed to underwriting the shortfall of the first $4 million, ensuring a minimum raise of $16 million.

Incentives for Investors

To sweeten the offer, Imugene is providing one free attaching listed option for every new share subscribed under the placement and SPP. These options have an exercise price of $0.18 and expire on 30 April 2027. Additionally, investors exercising these attaching options before expiry will receive piggyback options exercisable at $0.30, expiring in April 2029. If fully exercised, these options could inject up to an additional $20 million into the company, providing a potential extended funding runway.

Use of Proceeds

The capital raised will primarily fund the expansion of Imugene’s Phase 1b clinical trial for azer-cel, including the growth of Cohort 2 and the initiation of a new Cohort 3 that explores combination therapy with BTKi inhibitors. This development is critical for generating additional clinical data to support the therapy’s efficacy and safety profile. The funds will also extend the company’s financial runway into the fourth quarter of 2026 and cover general administrative expenses.

Convertible Notes Restructuring

In parallel with the capital raise, Imugene is restructuring its debt by redeeming and cancelling existing convertible notes issued to CVI Investments Inc., an affiliate of Heights Capital Management. The company will issue new senior convertible notes (SAR Notes) with a face value of approximately $15.3 million and warrants, subject to shareholder approval. These new instruments feature adjusted terms designed to improve Imugene’s cash flow position and provide greater financial flexibility.

The SAR Notes carry no interest and have a maturity date in January 2030, with conversion prices linked to the company’s share price and subject to adjustments. Warrants issued alongside the notes have a five-year term and an exercise price set at a premium to the reference price, offering CVI potential upside participation in Imugene’s equity growth.

Market and Strategic Implications

Imugene’s successful capital raise and debt restructuring signal strong institutional backing and a clear commitment to advancing its immuno-oncology pipeline. The funding will enable the company to accelerate clinical milestones for azer-cel, a promising off-the-shelf CAR T therapy targeting blood cancers, while managing financial risks through improved debt terms.

However, the issuance of new shares and options will dilute existing shareholders, a factor that investors will weigh against the potential value creation from clinical progress. The upcoming shareholder meeting to approve the options and convertible notes amendments will be a key event to watch.